Tauvid is owned by Avid Radiopharms Inc.
Tauvid contains Flortaucipir F-18.
Tauvid has a total of 1 drug patent out of which 0 drug patents have expired.
Tauvid was authorised for market use on 28 May, 2020.
Tauvid is available in solution;intravenous dosage forms.
Drug patent challenges can be filed against Tauvid from May, 2024.
The generics of Tauvid are possible to be released after 19 May, 2029.
|Patent Number||Company||Patent Title||Patent Expiry||Activity Alert|
|These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.|
|US8932557||AVID RADIOPHARMS INC||Imaging agents for detecting neurological dysfunction|| |
(6 years from now)
|New Chemical Entity Exclusivity (NCE)||May 28, 2025|
NCE-1 date: May, 2024
Market Authorisation Date: 28 May, 2020
Click on the highlighted region to filter.
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic